

Remarks

Please enter the above amendments prior to substantive examination. Upon entry of the above amendments, this application will contain claims 1-24 pending and under consideration. It is believed that the claims are patentable. Applicants respectfully request timely examination of this application leading to allowance of all claims.

Claim 1 has been amended to delete reference to a "solvate" of the compound of formula 1. In addition the following minor typographical errors have been corrected: on line 1 of the R¹ group listing hydrogen has been added (for support see claim 2); on line 6 of the R¹ group listing -OC₂-C₆cyan has been corrected to -OC₂-C₆alkylcyan; on line 8 of the R⁹ Markush group listing "alkynylaryl" has been corrected as --alkynylaryl--; on line 10 of the R⁹ group listing --C₁-C₆alkylCO₂R¹¹-- added (for support see claim 3, line 7).

Claim 2 has been amended by deleting the term "alkyl" on line 7¹ and replacing "C₀-C₃alkylCONH₂" with --CONH₂-- in the penultimate line to conform with the group listing for R¹ of claim 1.

Claim 3 on line 4 "alkyamine" has been replaced with --alkylamine--.

Claim 9 has been amended by inserting "the" in the penultimate line to correct a minor typographical error.

Claim 10 has been amended beginning on the 5th line after the structures by deleting "C(O) C₁-C₃ alkyl, C(O) C₃-C₆ cycloalkyl, C₁-C₃ alkylCONR⁷R⁸, C₁-C₃ alkylcyan, C₁-C₃ alkylCO₂R¹¹, C₁-C₃ and replacing "alkyINR⁷R⁸" with --C₁-C₃ alkylamine-- to conform to the listing in claim 1.

Claims 2-13, 15 18, 21 have been amended to recite a compound or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

Claims 15-17, and 19 have been amended to depend from claim 1 and by deleting reference to "solvates". In addition claims 16, 17, and 20 have been amended by deleting the term "preventing".

Claim 22 has been canceled.

New Claims 23 and 24 have been added. Support for these claims can be found in the published PCT application on page 3 lines 1-10, and page 10, lines 5-14 *inter alia*.

¹ In reference to the published PCT application, publication no. WO 2005/097805.

It is believed that these amendments do not add new matter. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this Response or other issues that may be resolved in that fashion.

Respectfully submitted,

/James B. Myers/

James B. Myers, Ph.D.
Attorney for Applicants
Registration No. 42,021
Phone: 317-276-0755

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

September 8, 2006